Femtech as an industry has been growing steadily over recent years.
What started as a niche sector focused on women’s health has evolved into a huge industry helping people track, manage and optimise their bodies.
According to Fortune Business Insights, the global femtech market was valued at $9.12 billion in 2025, and it isn’t showing signs of slowing down.
In fact, according to Dealroom, 9 femtech unicorns now exist around the world, with North America and EMEA leading the charge.
What Does FemTech Mean?
FemTech (or female technology) is a term coined by Clue founder Ida Tin, and includes any tech-driven product, software or service that focuses on women’s health. This could cover areas like menstrual health, fertility, menopause, pregnancy, sexual wellness and more.
Whilst FemTech started as a relatively niche sector, even mainstream tech companies are now cashing in on the action, developing apps, wearables and devices to help women optimise their health.
So as the industry grows and evolves, the real question is: who is driving it?
Here, we look at the biggest femtech funding rounds in 2025, showing the startups truly revolutionising women’s health.
Oura: $900 million (October)
Back in October, Oura announced that it has raised over $900 million in a Series E funding round, marking one of the biggest raises in the FemTech space.
Whilst not specifically a FemTech company, Oura’s technology is able to measure basal body temperature and track menstruation, helping women more easily measure their vitals.
Round: Series E
Post-Raise Valuation: $11 billion
Led by: Fidelity Management & Research Company
Tubulis: €344 million (October)
In late 2025, German biotech startup Tubulis raised €308 million in October and then closed a second round to reach a total of €344 million within the same month.
Tubulis are setting out to develop an antibody drug specifically designed to target an antigen that is expressed in ovarian cancer and lung adenocarcinomas. Whilst Tubulis isn’t technically only a femtech company, their research into ovarian cancer will change the lives of women around the world.
Round: Series C
Led by: Ventock
Future Family: $400 million (April)
Future Family is a company setting out to help couples afford fertility treatments. As current options are incredibly expensive, Future Family provides low-interest loans for treatments like IVF and egg freezing, as well as online support to help couples throughout the process.
Round: Financing
Led by: Clear Haven Capital Management
Hims & Hers: $1 billion (June)
Hims & Hers, a telehealth platform known for its direct-to-consumer approach to wellbeing and health, raised a round of debt financing to help with international expansion, even better personalisation and to boost investment in AI.
Currently Hims & Hers splits products into those for men and those for women. The Hers platform focuses on women’s health, particularly in areas like skin care, birth control and sexual health.
Round: Debt financing
Conceivable Life Sciences: $50 million (September)
Conceivable Life Sciences is setting out to make IVF more effective using AI and robotic precision.
Currently, the IVF cycle is very manual, meaning there is a certain degree of human error. Through their AI platform Aura, Conceivable is setting out to make the process more precise and reliable, by finding the best sperm, eggs and incubation environment. Through the latest fundraise, they are hoping to expand their research and improve IVF outcomes for couples around the world.
Round: Series A
Led by: ARTIS ventures, Stride and ACME ventures.
Mercy BioAnalytics: $59 million (September)
Mercy BioAnalytics is a company that is working on early cancer detection, with a specific focus on blood-based ovarian and lunch cancer tests.
Through their latest funding round, they are setting out to make early detection of ovarian cancer easier. Currently, ovarian cancer is one of the harder ones to diagnose, with many diagnoses happening too late. With their new research, Mercy BioAnalytics is setting out to change this.
Round: Series B
Post-Raise Valuation:
Visby Medical: $55 million (June)
Visby Medical announced a $55 million raise in order to release its at home STI test for women, which has recently been FDA approved.
The company is setting out to empower women with reliable, lab-grade tests from the comfort of their homes, starting with their STI test.
Round: Financing
Led by: Catalio Capital Management
Diana Health: $55 million (September)
Diana Health is a network of women’s health practices that partners with hospitals to provide personalised care. As part of the round, Diana Health is looking to expand both in-person and online.
Launched in 2020, Diana operates its health programmes in labour and women’s health clinics, partnering with clinicians to provide more holistic care.
Round: Series C
Led by: HealthQuest Capital
